A fast and accurate diagnosis can be critical when developing a treatment plan for any condition or disease. Without the right diagnostic tools and testing capabilities, it can be challenging to distinguish between viral and bacterial illnesses. Because respiratory illnesses can mimic similar symptoms, reliable testing remains a priority among physicians diagnosing COVID-19 from the flu, RSV, or Strep A.
Henry Schein Medical offers a robust portfolio of molecular testing options that can be administered at the point of care. With rapid results in minutes, rather than hours and days, it may be possible for you to:
Our molecular testing portfolio includes:
Combining the benefits of speed and accuracy, ID Now delivers lab accurate results that empowers physicians to make effective decisions for their patient's treatment plans.
Moving Molecular Testing Beyond the Lab
Simple, Integrated Workflow
Contact your Henry Schein Sales Consultant for additional assays available
Solana is a bench top instrument that combines Quidel's proprietary helicase-dependent amplification (HDA) with fluorescence detection to deliver molecular results you can trust.
The Solana testing system is easily accessible and can be seamlessly integrated. The workflow is simple, flexible, and has the ability to test a single specimen or batching up to 12 tests at a time.
Solana offers an intuitive, touch-screen interface with guided operation and customizable settings. The instrument possesses four USB ports, bar code technology, an external printer, and LIS connectivity. Results are reported on the screen, stored in the instrument, and can be saved to a USB drive, printed, and/or sent to the LIS.
Solana also comes with the power of Virena®, Quidel's proprietary wireless data management and surveillance ecosystem.
Laboratories face many challenges, including staff recruitment and retention, cost-containment pressures, increasing test volumes, and diagnostic inaccuracies. The BD MAX System is designed to help address today's challenges, while preparing your laboratory for tomorrow's possibilities.
The BD MAX System:
2. Hirvonen JJ et al. Comparison of BD Max Cdiff and GenomEra C. difficile molecular assays for detection of toxigenic Clostridium difficile from stools in conventional sample containers and in FecalSwabs. Eur J Clin Microbiol Infect Dis. 2015;34(5):1005-1009; 3. Bauman M. Transitioning from culture to molecular: implementation and integration of BD MAXTM Enteric Bacterial Panel at Cincinnati Children's Hospital. BD Advertorial. Franklin Lakes, NJ: Becton, Dickinson and Company; 2015; 7. Felder RA et al. Process evaluation of an open architecture real-time molecular laboratory platform. J Lab Autom. 2014;19(5):468- 473; 8. BD MAXTM Enteric Bacterial Panel [package insert]. Becton, Dickinson and Company: Franklin Lakes, NJ; 2016